嘉和生物-B(06998)今日盘中大涨5.11%，表现显著强于大盘。
消息面上，嘉和生物药业（开曼）控股有限公司已通过港交所上市聆讯，这意味着该公司在港交所的IPO进程取得重要进展。根据招股书，嘉和生物主要从事肿瘤及自体免疫药物的开发及商业化，产品管线覆盖乳腺癌、肺癌及胃肠道肿瘤等全球前三大肿瘤靶标。此次通过聆讯，尤其是其与亿腾医药的反向并购计划，增强了市场对公司未来发展的信心。
嘉和生物此次上市将依据《上市规则》第18A章，成为香港首宗未盈利生物科技公司反向并购案例。交易完成后，公司将更名为“亿腾嘉和医药集团有限公司”，进一步整合资源并扩大市场影响力。这一里程碑事件被视为推动股价上涨的关键因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.